{"id":787138,"date":"2023-09-29T12:52:24","date_gmt":"2023-09-29T16:52:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/"},"modified":"2023-09-29T12:52:24","modified_gmt":"2023-09-29T16:52:24","slug":"shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/","title":{"rendered":"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Sept.  29, 2023  (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in <strong>Apellis Pharmaceuticals, Inc.<\/strong> (&#8220;Apellis&#8221; or the &#8220;Company&#8221;) (NASDAQ: APLS) of a class action securities lawsuit.<\/p>\n<p>\n        <strong>CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Apellis investors who were adversely affected by alleged securities fraud between January 28, 2021 and July 28, 2023. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/zlk.com\/pslra-1\/apellis-lawsuit-submission-form?prid=49863&amp;wire=3\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/zlk.com\/pslra-1\/apellis-lawsuit-submission-form?prid=49863&amp;wire=3<\/a>\n      <\/p>\n<p>\n        <strong>APLS<\/strong> investors may also contact Joseph E. Levi, Esq. via email at\u00a0<a href=\"mailto:jlevi@levikorsinsky.com\" rel=\"nofollow noopener\" target=\"_blank\">jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n<p>\n        <strong>CASE DETAILS: <\/strong>The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants\u2019 statements about the Company\u2019s business, operations, and prospects lacked a reasonable basis.<\/p>\n<p>\n        <strong>WHAT&#8217;S NEXT? <\/strong>If you suffered a loss in Apellis during the relevant time frame, you have until <strong>October 2, 2023<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <strong>NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <strong>There is no cost or obligation to participate.<\/strong><\/p>\n<p>\n        <strong>WHY LEVI &amp; KORSINSKY: <\/strong>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/>Joseph E. Levi, Esq.<br \/>Ed Korsinsky, Esq.<br \/>33 Whitehall Street, 17th Floor<br \/>New York, NY 10004<br \/><a href=\"mailto:jlevi@levikorsinsky.com\" rel=\"nofollow noopener\" target=\"_blank\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"http:\/\/www.zlk.com\" rel=\"nofollow noopener\" target=\"_blank\">www.zlk.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2MxNTdjOTQtYzllNy00OTJkLWE2NTUtNWYzYzU1ODlmYzg4LTEwMzIyOTM=\/tiny\/Levi-Korsinsky-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. (&#8220;Apellis&#8221; or the &#8220;Company&#8221;) (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who were adversely affected by alleged securities fraud between January 28, 2021 and July 28, 2023. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/apellis-lawsuit-submission-form?prid=49863&amp;wire=3 APLS investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-787138","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. (&#8220;Apellis&#8221; or the &#8220;Company&#8221;) (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who were adversely affected by alleged securities fraud between January 28, 2021 and July 28, 2023. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/apellis-lawsuit-submission-form?prid=49863&amp;wire=3 APLS investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify &hellip; Continue reading &quot;SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-29T16:52:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline\",\"datePublished\":\"2023-09-29T16:52:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/\"},\"wordCount\":372,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/\",\"name\":\"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=\",\"datePublished\":\"2023-09-29T16:52:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline - Market Newsdesk","og_description":"NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. (&#8220;Apellis&#8221; or the &#8220;Company&#8221;) (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who were adversely affected by alleged securities fraud between January 28, 2021 and July 28, 2023. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/apellis-lawsuit-submission-form?prid=49863&amp;wire=3 APLS investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify &hellip; Continue reading \"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-29T16:52:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline","datePublished":"2023-09-29T16:52:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/"},"wordCount":372,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/","name":"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=","datePublished":"2023-09-29T16:52:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDc1MyM1ODM4NzE4IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-levi-korsinsky-notifies-apellis-pharmaceuticals-inc-apls-investors-of-a-class-action-lawsuit-and-upcoming-deadline-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Levi &amp;\u00a0Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS)\u00a0Investors of a Class Action Lawsuit and Upcoming Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=787138"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787138\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=787138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=787138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=787138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}